BioIT World’s Paul Nicholas examines Precision for Medicine’s new PATH immuno-analytics platform.
Precision’s Lakdawalla on the BBC: ‘You can’t just ban Twinkies’
Precision’s Darius Lakdawalla was recently interviewed for the BBC’s Business Daily program, discussing the trend to ban large size sodas and other recent anti-junk food measures.
AMCP News&Views caught up recently with Dan Renick, BS Pharmacy, RPh, President of Precision for Value, to get his thoughts on becoming a corporate member and innovations at his company.
TPG’s $75 million investment in Precision Medical Group is featured in Medical Marketing & Media.
PharmaLive covers TPG’s significant investment in Precision Medicine Group
TPG partner Kevin Hobart discusses the equity firm’s investment in Precision Medicine Group with Damian Garde for Fierce Biotech,
Leader in Healthcare Investing Acquires Stake in Growing Pharmaceutical Services Company
Fort Worth, Texas, San Francisco and Bethesda, MD — December 22, 2015 — TPG Growth, the middle market and growth equity investment platform of TPG, a leading global private investment firm with approximately $70 billion of assets under management, today announced a $75 million investment in Precision for Medicine, Inc. Additional details of the transaction were not disclosed.
Precision for Medicine’s Karen M. Becker, PhD, Managing Director, Translational and Regulatory Science, is quoted in an article regarding the upcoming Food and Drug Administration’s guidance on how it plans to oversee lab-developed tests used to diagnose conditions. Read the full article below:
By Andrew Siddons
Precision for Value’s Jeremy Schafer is quoted in an article that discusses the naming of biosimilars. He concludes that the payer community will find a way to track biosimilar sourcing, usage and reimbursement regardless of naming conventions or HCPCS codes.
Karen M. Becker, PhD, Managing Director, Translational and Regulatory Sciences at Precision for Medicine, provides expertise for the diagnostics industry in navigating the complexities of the Food and Drug Administration.